{"id":"W3131063362","doi":"10.1056/nejmoa2035716","title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Western University; University Hospital Foundation","funders":"Merck Sharp and Dohme; National Cancer Institute; Eisai","keywords":"Lenvatinib; Pembrolizumab; Everolimus; Sunitinib; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001503359,0.0004546729,0.001420668,0.0003304254,0.0002665953,0.0004117384,0.0003535048,0.000471977,0.003026243],"category_scores_gemma":[0.001016719,0.0002371963,0.0008534311,0.0003527842,0.0004538099,0.0003117735,0.0002808914,0.001070404,0.0004304672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005291054,"about_ca_system_score_gemma":0.001050928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003705579,"about_ca_topic_score_gemma":0.001510816,"domain_scores_codex":[0.999335,0.0003389235,0.0000718769,0.0001047264,0.00008827261,0.00006117696],"domain_scores_gemma":[0.999428,0.0002116547,0.0001094164,0.00002374587,0.00002045798,0.0002067019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7803607,0.007717006,0.01677394,0.001781409,0.002381054,0.0002273196,0.0001047088,0.003486213,0.01065779,0.0003797465,0.002359209,0.1737709],"study_design_scores_gemma":[0.6477081,0.2944326,0.0399048,0.0002214514,0.001857492,0.0007701118,0.0000615582,0.003220636,0.003867353,0.000732278,0.007189097,0.00003451403],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864341,0.00859126,0.0004032055,0.0004092673,0.0001962508,0.001588011,0.0003245689,0.00002739259,0.002025876],"genre_scores_gemma":[0.9951175,0.002249116,0.0006200323,0.0003446212,0.0001665721,0.000609597,0.0002696828,0.000004373733,0.0006185224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003026243,"threshold_uncertainty_score":0.01012379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03799850471779221,"score_gpt":0.294172294434195,"score_spread":0.2561737897164028,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}